[1 July 2016] The IBTA’s monthly e-News has now been released and has been emailed to all subscribers.
Some of the highlights from the June issue include:
- “We’ve reached an inflection point in our fight against cancer,” announced US Vice President Joe Biden, whose son died of a brain tumour, at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO 2016), held in Chicago in June
- Two separate studies find out that elderly glioblastoma patients live longer with combined chemotherapy and radiation therapy
- A clinical trial has shown that a technology that uses microbubble injections combined with an implanted ultrasound device can disrupt the blood-brain barrier in glioblastoma patients, allowing chemotherapy drugs to enter the tumour
- A research study points to a link between dopamine and glioblastoma growth
- Results from a phase 1 trial of Toca 511 and Toca FC, a modified virus that carries a gene into tumour cells combined with a drug that targets the modified tumour cells, have shown that patients with recurrent glioblastoma have extended survival
- Analysis of blood samples from 110 people who went on to develop glioblastoma has indicated that high levels of vitamin E could be a risk factor
- Clinical trials for immunotherapy in childhood DIPG tumours, and for young people and children with ependymoma are now recruiting patients
- An observational study has suggested that people with higher levels of education and greater earnings have a greater risk of being diagnosed with a brain tumour
- You can read the IBTA e-News June edition online here
Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to nearly 7,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News by registering here.
To see an archive of existing e-News issues, click here.
